Understand the source comparison
VIP Review 2026: Peptide Comparison Table
The table below compares VIP to other immune-modulating and neuroprotective peptides commonly used in research, highlighting receptor mechanisms, primary applications, and key considerations for experimental design. VIP VPAC1/VPAC2 agonist; elevates cAMP; supp
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares VIP to other immune-modulating and neuroprotective peptides commonly used in research, highlighting receptor mechanisms, primary applications, and key considerations for experimental design.
- VIP
- VPAC1/VPAC2 agonist; elevates cAMP; suppresses NF-κB
- Autoimmune models, neuroinflammation, circadian research, sepsis
- 1–2 min (plasma)
- Requires fresh reconstitution; degrades rapidly; dose timing critical
- Thymosin Alpha 1
- TLR agonist; enhances T-cell maturation and dendritic cell function
- Immunodeficiency models, vaccine adjuvant research, cancer immunology
- 2–3 hours
- More stable than VIP; suitable for multi-day protocols
- KPV
- C-terminal tripeptide of α-MSH; anti-inflammatory via inhibition of NF-κB
- IBD models, wound healing, dermatological inflammation
- 4–6 hours
- Oral and topical bioavailability; less systemic than VIP
- Cerebrolysin
- Mixture of neuropeptides; neurotrophic effects via BDNF/NGF pathways
- Stroke models, TBI, neurodegenerative disease
- Hours (complex mixture)
- Heterogeneous composition; batch variation possible
- Semax
- ACTH(4-10) analog; modulates BDNF and monoamine systems
- Cognitive research, neuroprotection, stress response
- 30–60 min
- Intranasal administration common; crosses BBB more readily